GlassScriptPhysician profile
Jordan Daniel Awerbach
NPI 1821314386
$12,178.46
in general payments reported to CMS, 2019-2025
7 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Adult Congenital Heart Disease provider received nationally (typical 2025 total: $272).
See the full distribution for Adult Congenital Heart Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2021: $4,988 · 2022: $1,050 · 2023: $5,820 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,295 · Travel and Lodging: $1,189 · Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,295.00 |
| Travel and Lodging | $1,188.83 |
| Food and Beverage | $468.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $10,332.50 | 2021-2023 | Opsumit |
| Actelion Pharmaceuticals, LTD | $1,401.84 | 2023 | Uptravi |
| Ge Healthcare | $132.76 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $123.06 | 2023 | Opsumit, Uptravi |
| Philips North America LLC | $114.27 | 2019 | |
| Medtronic Vascular, INC. | $74.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Awerbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.